UBS Group Lowers Celsius (NASDAQ:CELH) Price Target to $92.00

Celsius (NASDAQ:CELH - Get Free Report) had its price target reduced by research analysts at UBS Group from $99.00 to $92.00 in a note issued to investors on Wednesday, Benzinga reports. The firm currently has a "buy" rating on the stock. UBS Group's target price indicates a potential upside of 19.28% from the stock's previous close.

A number of other brokerages have also recently weighed in on CELH. Morgan Stanley reissued an "equal weight" rating and issued a $75.00 price target on shares of Celsius in a research report on Wednesday, March 27th. Roth Mkm boosted their target price on Celsius from $90.00 to $105.00 and gave the company a "buy" rating in a report on Thursday, March 14th. Maxim Group raised their price target on Celsius from $100.00 to $110.00 and gave the stock a "buy" rating in a research note on Monday, April 1st. Stifel Nicolaus reduced their price objective on Celsius from $95.00 to $85.00 and set a "buy" rating for the company in a research note on Thursday, May 2nd. Finally, Stifel Europe lifted their target price on shares of Celsius from $90.00 to $95.00 and gave the company a "buy" rating in a report on Monday, March 18th. Two analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $84.95.

Celsius Price Performance

Shares of Celsius stock traded up $0.18 during trading on Wednesday, hitting $77.13. 5,832,819 shares of the stock were exchanged, compared to its average volume of 4,793,541. The stock has a market cap of $17.82 billion, a price-to-earnings ratio of 99.74, a price-to-earnings-growth ratio of 2.22 and a beta of 1.93. The firm's 50-day moving average price is $81.42 and its 200 day moving average price is $65.97. Celsius has a 12-month low of $34.74 and a 12-month high of $99.62.

Celsius (NASDAQ:CELH - Get Free Report) last announced its quarterly earnings results on Tuesday, May 7th. The company reported $0.27 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.20 by $0.07. Celsius had a return on equity of 131.58% and a net margin of 17.21%. The company had revenue of $355.70 million during the quarter, compared to the consensus estimate of $390.37 million. During the same period in the previous year, the business earned $0.13 EPS. Celsius's revenue for the quarter was up 36.9% on a year-over-year basis. As a group, research analysts forecast that Celsius will post 1.09 earnings per share for the current year.

Insiders Place Their Bets

In other Celsius news, major shareholder Dean Desantis sold 100,000 shares of the company's stock in a transaction dated Wednesday, March 13th. The shares were sold at an average price of $95.75, for a total transaction of $9,575,000.00. Following the transaction, the insider now directly owns 219,257 shares in the company, valued at $20,993,857.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Celsius news, Director Nicholas Castaldo sold 165,000 shares of the firm's stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $83.33, for a total transaction of $13,749,450.00. Following the completion of the transaction, the director now directly owns 352,864 shares in the company, valued at approximately $29,404,157.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Dean Desantis sold 100,000 shares of the company's stock in a transaction dated Wednesday, March 13th. The shares were sold at an average price of $95.75, for a total transaction of $9,575,000.00. Following the completion of the sale, the insider now directly owns 219,257 shares in the company, valued at approximately $20,993,857.75. The disclosure for this sale can be found here. Over the last quarter, insiders sold 2,043,363 shares of company stock worth $131,361,140. 2.20% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Celsius

Institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. raised its holdings in Celsius by 183.6% in the 4th quarter. Vanguard Group Inc. now owns 13,746,472 shares of the company's stock valued at $749,458,000 after acquiring an additional 8,899,873 shares during the last quarter. Wellington Management Group LLP increased its stake in Celsius by 212.2% in the fourth quarter. Wellington Management Group LLP now owns 3,393,586 shares of the company's stock valued at $185,018,000 after purchasing an additional 2,306,598 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in Celsius by 424.9% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,793,210 shares of the company's stock worth $152,287,000 after buying an additional 2,261,046 shares during the period. Eagle Asset Management Inc. boosted its stake in Celsius by 188.8% in the 4th quarter. Eagle Asset Management Inc. now owns 2,958,771 shares of the company's stock worth $161,312,000 after buying an additional 1,934,400 shares during the last quarter. Finally, Artisan Partners Limited Partnership purchased a new stake in Celsius in the 4th quarter valued at about $101,116,000. 60.95% of the stock is owned by institutional investors and hedge funds.

About Celsius

Celsius Holdings, Inc develops, processes, markets, distributes, and sells functional energy drinks and liquid supplements in the United States, Australia, New Zealand, Canadian, European, Middle Eastern, Asia-Pacific, and internationally. The company offers CELSIUS, a fitness drink or supplement designed to accelerate metabolism and burn body fat; various flavors and carbonated and non-carbonated functional energy drinks under the CELSIUS Originals and Vibe name, as well as functional energy drink under the CELSIUS Essentials and CELSIUS On-the-Go Powder names; and CELSIUS ready-to drink products.